参考文献

［1］ ZHANG L, LONG J, JIANG W, et al. Trends in chronic kidney disease in china [J]. N Engl J Med, 2016, 375 (9): 905-906.

［2］ UMANATH K, LEWIS J B. Update on diabetic nephropathy: Core curriculum 2018 [J]. Am J Kidney Dis, 2018, 71 (6): 884-895.

［3］ MOLITCH M E, ADLER A I, FLYVBJERG A, et al. Diabetic kidney disease: A clinical update from kidney disease: Improving global outcomes [J]. Kidney int, 2015, 87 (1): 20-30.

［4］ DUNKLER D, GAO P, LEE S F, et al. Risk prediction for early CKD in type 2 diabetes [J]. Clin J Am Soc Nephrol, 2015, 10 (8): 1371-1379.

［5］ DE COSMO S, VIAZZI F, PACILLI A, et al. Serum uric acid and risk of CKD in type 2 diabetes [J]. Clin J Am Soc Nephrol, 2015, 10 (11): 1921-1929.

［6］ KLESSENS C Q, WOUTMAN T D, VERAAR K A, et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed [J]. Kidney int, 2016, 90 (1): 149-156.

［7］ MOTTL A K, GASIM A, SCHOBER F P, et al. Segmental sclerosis and extracapillary hypercellularity predict diabetic ESRD [J]. J Am Soc Nephrol, 2018, 29 (2): 694-703.

［8］ Summary of revisions: standards of medical care in diabetes-2019 [J]. Diabetes care, 2019, 42 (Suppl 1): S4-S6.

［9］ BARRIOS C, PASCUAL J, OTERO S, et al. Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease [J]. Atherosclerosis, 2015, 242 (1): 37-44.

［10］ KHATIR D S, PEDERSEN M, JESPERSEN B, et al. Evaluation of renal blood flow and oxygenation in CKD using magnetic resonance imaging [J]. Am J Kidney Dis, 2015, 66 (3): 402-411.

［11］ TONNUS W, HUGO C, LINKERMANN A. Gimme a complex！Resident mononuclear phagocytes in the kidney as monitors of circulating antigens and immune complexes [J]. Kidney Int, 2017, 91 (2): 267-269.

［12］ 剧孟磊, 左洋洋, 赖宇雄, 等. 线粒体活性氧—糖尿病肾病进展的中心环节 [J]. 中华肾脏病杂志, 2015, 31 (11): 866-869.

［13］ 王惠珍, 文枫, 王文健. 非编码RNA参与糖尿病肾病发病的机制及其诊疗价值 [J]. 中华肾脏病杂志, 2015, 32 (9): 708-712.

［14］ 李静, 梁田田, 王文健. 糖尿病肾病的早期诊断 [J]. 中华肾脏病杂志, 2017, 33 (6): 470-775.

［15］ IKIZLER T A, ROBINSON-COHEN C, ELLIS C, et al. Metabolic effects of diet and exercise in patients with moderate to severe CKD: A randomized clinical trial [J]. J Am Soc Nephrol, 2018, 29 (1): 250-259.

［16］ BAKRIS G L, AGARWAL R, CHAN J C, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial [J]. JAMA, 2015, 314 (9): 884-894.

［17］ BAKRIS G L, PITT B, WEIR M R, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The amethyst-dn randomized clinical trial [J]. JAMA, 2015, 314(2): 151-161.

［18］ STERNS R H, GRIEFF M, BERNSTEIN P L. Treatment of hyperkalemia: Something old, something new [J]. Kidney int, 2016, 89 (3): 546-554.

［19］ ZINMAN B, WANNER C, LACHIN J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes [J]. N Engl J Med, 2015, 373 (22): 2117-2128.

［20］ PERKOVIC V, JARDINE M J, NEAL B et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [J]. N Engl J Med, 2019, 380: 2295-2306.

［21］ YE Z, SHARP SJ, BURGESS S, et al. Association between circulating 25-hydroxyvitamin d and incident type 2 diabetes: A mendelian randomisation study [J]. Lancet Diabetes Endocrinol, 2015, 3 (1): 35-42.

［22］ O′SHAUGHNESSY M M, LIU S, MONTEZ-RATH M E, et al. Kidney transplantation outcomes across gn subtypes in the united states [J]. J Am Soc Nephrol, 2017, 28 (2): 632-644.

［23］ WANG X. Gene mutation-based and specific therapies in precision medicine [J]. J Cell Mol Med, 2016, 20 (4): 577-580.

［24］ BOON R A, JAE N, HOLDT L, et al. Long noncoding rnas: From clinical genetics to therapeutic targets [J]？J Am Coll Cardiol, 2016, 67 (10): 1214-1226.

［25］ WEN C P, CHANG C H, TSAI M K, et al. Diabetes, with early kidney involvement may shorten life expectancy by 16 years [J]. Kidney Int, 2017, 92 (2): 388-396.

［26］ LEITER L A, TEOH H, BRAUNWALD E, et al. Efficacy and safety of saxagliptin in older participants in the savor-timi 53 trial [J]. Diabetes care, 2015, 38 (6): 1145-1153.

［27］ ZANNAD F, CANNON CP, CUSHMAN WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in examine: A multicentre, randomised, double-blind trial [J]. Lancet, 2015, 385 (9982): 2067-2076.

［28］ GREEN J B, BETHEL M A, ARMSTRONG P W, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes [J]. N Engl J Med, 2015, 373 (3): 232-242.

［29］ SHETH K N, ELM J J, MOLYNEAUX B J, et al. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): A randomised, double-blind, placebo-controlled phase 2 trial [J]. Lancet Neurol, 2016, 15 (11): 1160-1169.